drugset / Trial / NCT04091022
Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
Phase 2
Completed
64 enrolled
University of Alabama at Birmingham
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a single institution, randomized, placebo-controlled, double-blind phase IIB trial of 1) topical diclofenac and topical DFMO, or 2) placebo in participants with a history of non melanoma skin cancer/ keratinocytic cancers.
Timeline
- Start
- 2021-01-18
- Primary completion
- 2025-12-11
- Completion
- 2025-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Diclofenac | Other / unclassified | 3 % | Topical |
| Comparator | Eflornithine | Small molecule | 13.9 % | Topical |